Recombinant human GDPD1 protein; Source: E. coli derived, PGEX-4T; Tag: GST; Domain: 30-195 aa of BC034432
Conjugate
Unconjugated
Applications
Application Notes
WB: 1:5000-1:50000 IHC: 1:50-1:500
General Notes
This product (Catalog No. DPABH-08660) is a rabbit-derived polyclonal antibody raised against human GDPD1, targeting the amino acid region 30–195 of the protein. This antibody exhibits cross-reactivity with Human GDPD1 from mouse and rat. It has been affinity purified by Protein A. Glycerophosphodiester phosphodiesterase domain-containing protein 1 (GDPD1) is an enzyme that hydrolyzes lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and the corresponding amines. GDPD1 shows a preference for 1-O-alkyl-sn-glycero-3-phosphocholine (lyso-PAF), lysophosphatidylethanolamine (lyso-PE) and lysophosphatidylcholine (lyso-PC). GDPD1 may be involved in bioactive N-acylethanolamine biosynthesis from both N-acyl-lysoplasmenylethanolamin (N-acyl-lysoPlsEt) and N-acyl-lysophosphatidylethanolamin (N-acyl-lysoPE) (PMID:25596343, PMID:27637550). GDPD1 is widely expressed with a high expression level in testis. GDPD1 is a prognostic marker in Liver hepatocellular carcinoma. DPABH-08660 is suitable for use in Western blot (WB) (1:5,000–1:50,000), IHC (1:50–1:500) applications. DPABH-08660 is supplied as a liquid formulation in PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. For long-term storage, keep at −20 °C. For short-term use, store at 2–8 °C. Avoid repeated freeze–thaw cycles to maintain antibody integrity and performance.
Target
Alternative Names
EC:3.1.4.-; GDE4; Glycerophosphodiester phosphodiesterase domain-containing protein 1; Lysophospholipase D GDPD1; UGPQ
My Review for Rabbit Anti-Human GDPD1 (a.a. 30-195) Polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.